Clinical Pharmacokinetics

, Volume 41, Issue 14, pp 1135–1151 | Cite as

Pharmacokinetic and Pharmacodynamic Considerations When Treating Patients with Sepsis and Septic Shock

  • Peter De Paepe
  • Frans M. Belpaire
  • Walter A. Buylaert
Review Articles Special Populations

Abstract

Sepsis and septic shock are accompanied by profound changes in the organism that may alter both the pharmacokinetics and the pharmacodynamics of drugs. This review elaborates on the mechanisms by which sepsis-induced pathophysiological changes may influence pharmacological processes.

Drug absorption following intramuscular, subcutaneous, transdermal and oral administration may be reduced due to a decreased perfusion of muscles, skin and splanchnic organs. Compromised tissue perfusion may also affect drug distribution, resulting in a decrease of distribution volume. On the other hand, the increase in capillary permeability and interstitial oedema during sepsis and septic shock may enhance drug distribution. Changes in plasma protein binding, body water, tissue mass and pH may also affect drug distribution. For basic drugs that are bound to the acute phase reactant α1-acid glycoprotein, the increase in plasma concentration of this protein will result in a decreased distribution volume. The opposite may be observed for drugs that are extensively bound to albumin, as the latter protein decreases during septic conditions.

For many drugs, the liver is the main organ for metabolism. The determinants of hepatic clearance of drugs are liver blood flow, drug binding in plasma and the activity of the metabolic enzymes; each of these may be influenced by sepsis and septic shock. For high extraction drugs, clearance is mainly flow-dependent, and sepsis-induced liver hypoperfusion may result in a decreased clearance. For low extraction drugs, clearance is determined by the degree of plasma binding and the activity of the metabolic enzymes. Oxidative metabolism via the cytochrome P450 enzyme system is an important clearance mechanism for many drugs, and has been shown to be markedly affected in septic conditions, resulting in decreased drug clearance.

The kidneys are an important excretion pathway for many drugs. Renal failure, which often accompanies sepsis and septic shock, will result in accumulation of both parent drug and its metabolites.

Changes in drug effect during septic conditions may theoretically result from changes in pharmacodynamics due to changes in the affinity of the receptor for the drug or alterations in the intrinsic activity at the receptor.

The lack of valid pharmacological studies in patients with sepsis and septic shock makes drug administration in these patients a difficult challenge. The patients underlying pathophysiological condition may guide individual dosage selection, which may be guided by measuring plasma concentration or drug effect.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Bone RC, Balk R, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Crit Care Med 1992; 20: 864–74Google Scholar
  2. 2.
    Clowes GHA, Vucini M, Weidner MG. Circulatory and metabolic alterations associated with survival and death in peritonitis. Ann Surg 1966; 163: 866–85PubMedGoogle Scholar
  3. 3.
    Siegel J, Greenspan M, Del Guercio LRM. Abnormal vascular tone, defective oxygen transport, and myocardial failure in human septic shock. Ann Surg 1967; 165: 504–17PubMedGoogle Scholar
  4. 4.
    Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia, United States, 1979–1987. MMWR Morb Mortal Wkly Rep 1990; 39: 31–4Google Scholar
  5. 5.
    Bone RC. Sepsis, the sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 1991; 114: 332–3PubMedGoogle Scholar
  6. 6.
    Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278: 234–40PubMedGoogle Scholar
  7. 7.
    Parrillo JE. Pathogenetic mechanisms of septic shock. N Engl J Med 1993; 328: 1471–7PubMedGoogle Scholar
  8. 8.
    Power BM, Millar Forbes A, Vernon van Heerden P, et al. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998; 34: 25–56PubMedGoogle Scholar
  9. 9.
    Bodenham A, Shelly MP, Park GR. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet 1988; 14: 347–73PubMedGoogle Scholar
  10. 10.
    Heffner JE. A wake-up call in the intensive care unit. N Engl J Med 2000; 342: 1520–2PubMedGoogle Scholar
  11. 11.
    Pentel P, Benowitz N. Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies. Clin Pharmacokinet 1984; 9: 273–308PubMedGoogle Scholar
  12. 12.
    Jellet LB, Heazlewood VJ. Pharmacokinetics in acute illness. Med J Aust 1990; 153: 534–41Google Scholar
  13. 13.
    Neugebauer E, Dietrich A, Lechleuthner A, et al. Pharmacotherapy in shock syndromes: the neglected field of pharmacokinetics and pharmacodynamics. Circ Shock 1992; 36: 312–20PubMedGoogle Scholar
  14. 14.
    Park GR. Pharmacokinetics and pharmacodynamics in the critically ill patient. Xenobiotica 1993; 23: 1195–230PubMedGoogle Scholar
  15. 15.
    Wagner BKJ, O’Hara D. Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients. Clin Pharmacokinet 1997; 33: 426–53PubMedGoogle Scholar
  16. 16.
    Kennedy JM, Van Riji A. Effects of surgery on the pharmacokinetic parameters of drugs. Clin Pharmacokinet 1998; 35: 293–12PubMedGoogle Scholar
  17. 17.
    Verbeeck RK, Horsmans Y. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci 1998; 20: 183–92PubMedGoogle Scholar
  18. 18.
    McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy 1998; 18: 759–78PubMedGoogle Scholar
  19. 19.
    Shedlofsky SI, Israel BC, McClain CJ, et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994; 94: 2209–14PubMedGoogle Scholar
  20. 20.
    Shedlofsky SI, Israel BC, Tosheva R, et al. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol 1997; 43: 627–32PubMedGoogle Scholar
  21. 21.
    Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia 1987; 42: 619–26PubMedGoogle Scholar
  22. 22.
    Macnab MSP, Macrae DJ, Guy E, et al. Profound reduction in morphine clearance and liver blood flow in shock. Intensive Care Med 1986; 12: 366–9PubMedGoogle Scholar
  23. 23.
    Groeger JS, Inturrisi CE. High-dose naloxone: pharmacokinetics in patients in septic shock. Crit Care Med 1987; 15: 751–6PubMedGoogle Scholar
  24. 24.
    Beckhouse MJ, Whyte M, Byth PL, et al. Altered aminoglycoside pharmacokinetics in the critically ill. Anaesth Intensive Care 1988; 16: 418–22PubMedGoogle Scholar
  25. 25.
    Marik PE. Aminoglycoside volume of distribution and illness in critically ill septic patients. Anaesth Intensive Care 1993; 21: 172–3PubMedGoogle Scholar
  26. 26.
    Kinowski J, de la Coussaye J, Bressolle F, et al. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob Agents Chemother 1993; 37: 464–73PubMedGoogle Scholar
  27. 27.
    Lugo G, Castaneda-Hernandez G. Relationship between hemodynamic and vital support measures and pharmacokinetic variability of amikacin in critically ill patients with sepsis. Crit Care Med 1997; 25: 806–11PubMedGoogle Scholar
  28. 28.
    Mann HJ, Fuhs DW, Awang R, et al. Altered aminoglycoside pharmacokinetics in critically ill patients with sepsis. Clin Pharm 1987; 6: 148–53PubMedGoogle Scholar
  29. 29.
    Chelluri L, Warren J, Jastremski MS. Pharmacokinetics of a 3 mg/kg body weight loading dose of gentamicin or tobramycin in critically ill patients. Chest 1989; 95: 1295–7PubMedGoogle Scholar
  30. 30.
    Triginer C, Izquierdo I, Fernández R, et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med 1990; 16: 303–6PubMedGoogle Scholar
  31. 31.
    Tholl DA, Shikuma LR, Miller TQ, et al. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med 1993; 21: 248–51PubMedGoogle Scholar
  32. 32.
    Oparaoji EC, Cornwell EE, Hekmat E, et al. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin Pharm 1993; 12: 131–4PubMedGoogle Scholar
  33. 33.
    Peterson AK, Duffull SB. Population analysis of once-daily dosing of gentamicin in patients with neutropenia. Aust N Z J Med 1998; 28: 311–5PubMedGoogle Scholar
  34. 34.
    Tang GJ, Tang JJ, Lin BS, et al. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol Scand 1999; 43: 726–30PubMedGoogle Scholar
  35. 35.
    Kieft H, Hoepelman AIM, Knupp CA, et al. Pharmacokinetics of cefepime in patients with sepsis syndrome. J Antimicrob Chemother 1993; 32: 117–22PubMedGoogle Scholar
  36. 36.
    Pazin GJ, Schwartz SN, Ho M, et al. Treatment of septicemic patients with cefoxitin: pharmacokinetics in renal insufficiency. Rev Infect Dis 1979; 1: 189–94PubMedGoogle Scholar
  37. 37.
    Lipman J, Scribante J, Gous AGS, et al. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998; 42: 2235–9PubMedGoogle Scholar
  38. 38.
    Schrenzel J, Cerruti F, Herrmann M, et al. Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients. Antimicrob Agents Chemother 1994; 38: 1219–24PubMedGoogle Scholar
  39. 39.
    Winslade NE, Smith IL, Simons GW, et al. Pharmacokinetics and extravascular penetration of aztreonam in patients with abdominal sepsis. Rev Infect Dis 1985; 7: S716–23PubMedGoogle Scholar
  40. 40.
    Cornwell EE, Belzberg H, Berne TV, et al. Pharmacokinetics of aztreonam in critically ill surgical patients. Am J Health Syst Pharm 1997; 54: 537–40PubMedGoogle Scholar
  41. 41.
    Mann HJ, Townsend RJ, Fuhs DW, et al. Decreased hepatic clearance of clindamycin in critically ill patients with sepsis. Clin Pharm 1987; 6: 154–9PubMedGoogle Scholar
  42. 42.
    Toft P, Heslet L, Hansen M, et al. Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure. Intensive Care Med 1991; 17: 465–8PubMedGoogle Scholar
  43. 43.
    Poloyac SM, Tosheva RT, Gardner BM, et al. The effect of endotoxin administration on the pharmacokinetics of chlorzoxazone in humans. Clin Pharmacol Ther 1999; 66: 554–62PubMedGoogle Scholar
  44. 44.
    Gavin TJ, Fabian TC, Wilson JD, et al. Splanchnic and systemic hemodynamic responses to portal vein endotoxin after resuscitation from hemorrhagic shock. Surgery 1994; 115: 310–24PubMedGoogle Scholar
  45. 45.
    Astiz ME, DeGent GE, Lin RY, et al. Microvascular function and rheologic changes in hyperdynamic sepsis. Crit Care Med 1995; 23: 265–71PubMedGoogle Scholar
  46. 46.
    Dahn MS, Lange P, Lobdell K, et al. Splanchnic and total body oxygen consumption differences in septic and injured patients. Surgery 1987; 101: 69–80PubMedGoogle Scholar
  47. 47.
    Ruokonen E, Takala J, Kari A, et al. Regional blood flow and oxygen transport in septic shock. Crit Care Med 1993; 21: 1296–303PubMedGoogle Scholar
  48. 48.
    Meier-Hellmann A, Reinhart K, Bredle DL, et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit Care Med 1997; 25: 399–404PubMedGoogle Scholar
  49. 49.
    Reinelt H, Radermacher P, Kiefer P, et al. Impact of exogenous β-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med 1999; 27: 325–31PubMedGoogle Scholar
  50. 50.
    Takala J, Ruokonen E. Blood flow and adrenergic drugs in septic shock. In: Vincent JL, editor. Update in intensive care and emergency medicine. Berlin: Springer-Verlag, 1991: 144–52Google Scholar
  51. 51.
    Kiefer P, Tugtekin I, Wiedeck H, et al. Effect of a dopexamine-induced increase in cardiac index on splanchnic hemodynamics in septic shock. Am J Respir Crit Care Med 2000; 161: 775–9PubMedGoogle Scholar
  52. 52.
    Smithies M, Yee TH, Jackson L, et al. Protecting the gut and the liver in the critically ill: effect of dopexamine. Crit Care Med 1994; 22: 789–95PubMedGoogle Scholar
  53. 53.
    Maynard ND, Bihari DJ, Dalton RN, et al. Increasing splanchnic blood flow in the critically ill. Chest 1995; 108: 1648–54PubMedGoogle Scholar
  54. 54.
    Meier-Hellmann A, Bredle DL, Specht M, et al. The effects of low-dose dopamine on splanchnic blood flow and oxygen uptake in patients with septic shock. Intensive Care Med 1997; 23: 31–7PubMedGoogle Scholar
  55. 55.
    Nevière R, Mathieu MD, Chagnon JL, et al. The contrasting effects of dobutamine and dopamine on gastric mucosal perfusion in septic patients. Am J Respir Crit Care Med 1996; 154: 1684–8PubMedGoogle Scholar
  56. 56.
    Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272: 1354–7PubMedGoogle Scholar
  57. 57.
    Fink MP. Adequacy of gut oxygenation in endotoxemia and sepsis. Crit Care Med 1993; 21: S4–8PubMedGoogle Scholar
  58. 58.
    Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. New York: Macmillan Publishing Co Inc., 1996: 3–27Google Scholar
  59. 59.
    van Lambalgen AA, Bronsveld W, van den Bos GC, et al. Distribution of cardiac output, oxygen consumption and lactate production in canine endotoxin shock. Cardiovasc Res 1984; 18: 195–205PubMedGoogle Scholar
  60. 60.
    Lundberg D. The pharmacological basis of treatment with high dose corticosteroids in circulatory shock. Acta Chir Scand 1985; 526: 7–12Google Scholar
  61. 61.
    Whitworth PW, Cryer HM, Garrison RN, et al. Hypoperfusion of the intestinal microcirculation without decreased cardiac output during live Escherichia coli sepsis in rats. Circ Shock 1989; 27: 111–22PubMedGoogle Scholar
  62. 62.
    Hollenberg SM, Ahrens TS, Astiz ME, et al. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999; 27: 639–60Google Scholar
  63. 63.
    Hinshaw LB. Sepsis/septic shock: participation of the microcirculation, an abbreviated review. Crit Care Med 1996; 24: 1072–8PubMedGoogle Scholar
  64. 64.
    Flournoy DJ, Beller BK, Archer LT, et al. Relationship of serum gentamicin levels and methylprednisolone sodium succinate treatment in baboons challenged with Escherichia coli LD100. Clin Ther 1983; 5: 417–21PubMedGoogle Scholar
  65. 65.
    Beller BK, Archer LT, Passey RB, et al. Effectiveness of modified steroid/antibiotic therapies for lethal sepsis in the dog. Arch Surg 1983; 118: 1293–9PubMedGoogle Scholar
  66. 66.
    Hinshaw LB, Beller BK, Chang ACK, et al. Evaluation of naloxone for therapy of Escherichia coli shock. Arch Surg 1984; 119: 1410–8PubMedGoogle Scholar
  67. 67.
    Kreuzer F, Cain SM. Regulation of the peripheral vasculature and tissue oxygenation in health and disease. Crit Care Clin 1985; 1: 453–70PubMedGoogle Scholar
  68. 68.
    Ishihara H, Matsui A, Muraoka M, et al. Detection of capillary protein leakage by indocyanine green and glucose dilutions in septic patients. Crit Care Med 2000; 28: 620–6PubMedGoogle Scholar
  69. 69.
    Elsasser S, Schächinger H, Strobel W. Adjunctive drug treatment in severe hypoxic respiratory failure. Drugs 1999; 58: 429–46PubMedGoogle Scholar
  70. 70.
    Moore RD, Smith CR, Lietman PS. The association of amino-glycoside plasma levels with mortality in patients with gramnegative bacteremia. J Infect Dis 1984; 149: 443–8PubMedGoogle Scholar
  71. 71.
    Niemiec PW, Allo MD, Miller CF, et al. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987; 122: 207–12PubMedGoogle Scholar
  72. 72.
    Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988; 16: 327–30PubMedGoogle Scholar
  73. 73.
    Reimann IR, Meier-Hellmann A, Reinhart K, et al. Comments to consensus document: once daily dosing of aminoglycosides from N. Anaizi: a supplement to dosage and monitoring in critically ill patients. Int J Clin Pharmacol Ther 1997; 35: 397PubMedGoogle Scholar
  74. 74.
    Zaske DE, Cipolle RJ, Strate RG. Gentamicin dosage requirements: wide interpatient variations in 242 surgery patients with normal renal function. Surgery 1980; 87: 164–9PubMedGoogle Scholar
  75. 75.
    Hassan E, Ober J. Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients. Crit Care Med 1986; 14: 394–8Google Scholar
  76. 76.
    Zaske DE, Cipolle RJ, Rotschafer JC, et al. Gentamicin pharmacokinetics in 1640 patients: method for control of serum concentrations. Antimicrob Agents Chemother 1982; 21: 407–11PubMedGoogle Scholar
  77. 77.
    Whipple JK, Ausman RK, Franson T, et al. Effect of individualized pharmacokinetic dosing on patient outcome. Crit Care Med 1991; 19: 1480–5PubMedGoogle Scholar
  78. 78.
    Nau R, Sörgel F, Prange HW. Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet 1998; 35: 223–46PubMedGoogle Scholar
  79. 79.
    Lamy M. Acute-phase proteins and protease-antiproteases in the inflammatory reaction. In: Bihari D, Cerra FB, editors. New horizons: multiple organ failure. Fullerton (CA): Society of Critical Care Medicine, 1989: 193–217Google Scholar
  80. 80.
    Zielmann S, Mielck F, Kahl R. A rational basis for the measurement of free phenytoin concentration in critically ill trauma patients. Ther Drug Monit 1994; 16: 139–44PubMedGoogle Scholar
  81. 81.
    Vree TB, Shimoda M, Driessen JJ, et al. Decreased plasma albumin concentration results in increased volume of distribution and decreased elimination of midazolam in intensive care patients. Clin Pharmacol Ther 1989; 46: 537–44PubMedGoogle Scholar
  82. 82.
    Tuchschmidt J, Oblitas D, Fried JC. Oxygen consumption in sepsis and septic shock. Crit Care Med 1991; 19: 664–71PubMedGoogle Scholar
  83. 83.
    Elston AC, Bayliss MK, Park GR. Effect of renal failure on drug metabolism by the liver. Br J Anaesth 1993; 71: 282–90PubMedGoogle Scholar
  84. 84.
    Beal AL, Cerra FB. Multiple organ failure syndrome in the 1990s: systemic inflammatory response and organ dysfunction. JAMA 1994; 271: 226–33PubMedGoogle Scholar
  85. 85.
    Cerra FB, Siegel JH, Coleman B, et al. Septic autocannibalism: a failure of exogenous nutritional support. Ann Surg 1980; 192: 570–80PubMedGoogle Scholar
  86. 86.
    Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. Stamford: Appleton and Lange, 1999: 353–98Google Scholar
  87. 87.
    Belpaire FM, Bogaert MG. The fate of xenobiotics in living organisms. In: Wermuth CG, editor. The practice of medicinal chemistry. London: Academia Press, 1996: 593–614Google Scholar
  88. 88.
    Hebert MF. Guide to drug dosage in hepatic disease. In: Holford N, editor. Clinical pharmacokinetics: drug data handbook. Auckland (NZ): Adis International 1998: 121–79Google Scholar
  89. 89.
    Gump FE, Price JB, Kinney JM. Whole body and splanchnic blood flow and oxygen consumption measurements in patients with intraperitoneal infection. Ann Surg 1970; 171: 321–8PubMedGoogle Scholar
  90. 90.
    Wilmore DW, Goodwin CW, Aulick LH, et al. Effect of injury and infection on visceral metabolism and circulation. Ann Surg 1980; 192: 491–504PubMedGoogle Scholar
  91. 91.
    Wang P, Ba ZF, Chaudry IH. Hepatic extraction of indocyanine green is depressed early in sepsis despite increased hepatic blood flow and cardiac output. Arch Surg 1991; 126: 219–24PubMedGoogle Scholar
  92. 92.
    Bersten AD, Hersch M, Cheung H, et al. The effect of various sympathomimetics on the regional circulations in hyperdynamic sepsis. Surgery 1992; 112: 549–61PubMedGoogle Scholar
  93. 93.
    Wyler F, Forsyth RP, Nies AS, et al. Endotoxin-induced regional circulatory changes in the unanesthetized monkey. Circ Res 1969; 24: 777–86PubMedGoogle Scholar
  94. 94.
    Wang P, Ba ZF, Chaudry IH, et al. Increase in hepatic blood flow during early sepsis is due to increased portal blood flow. Am J Physiol 1991; 261: R1507–12PubMedGoogle Scholar
  95. 95.
    Wang P, Zhou M, Rana MW, et al. Differential alterations in microvascular perfusion in various organs during early and late sepsis. Am J Physiol 1992; 263: G38–43PubMedGoogle Scholar
  96. 96.
    Wang P, Ba ZF, Tait SM, et al. Alterations in circulating blood volume during polymicrobial sepsis. Circ Shock 1993; 40: 92–8PubMedGoogle Scholar
  97. 97.
    Wang P, Ba ZF, Chaudry IH. Hepatocellular dysfunction occurs earlier than the onset of hyperdynamic circulation during sepsis. Shock 1995; 3: 21–6PubMedGoogle Scholar
  98. 98.
    Ayuse T, Brienza N, Revelly JP, et al. Alterations in liver hemodynamics in an intact porcine model of endotoxin shock. Am J Physiol 1995; 268: H1106–14PubMedGoogle Scholar
  99. 99.
    Garrison RN, Ratcliffe DJ, Fry DE. Hepatocellular function and nutrient blood flow in experimental peritonitis. Surgery 1982; 92: 713–9PubMedGoogle Scholar
  100. 100.
    Gutierrez G, Bismar H, Dantzker DR, et al. Comparison of gastric intramucosal pH with measures of oxygen transport and consumption in critically ill patients. Crit Care Med 1992; 20: 451–7PubMedGoogle Scholar
  101. 101.
    De Backer D, Creteur J, Noordally O, et al. Does hepatosplanchnic VO2/DO2 dependency exist in critically ill patients? Am J Respir Crit Care Med 1998; 157: 1219–25PubMedGoogle Scholar
  102. 102.
    Gutierrez G, Clark C, Brown SD, et al. Effect of dobutamine on oxygen consumption and gastric mucosal pH in septic patients. Am J Respir Crit Care Med 1994; 150: 324–9PubMedGoogle Scholar
  103. 103.
    Marik PE. Gastric intramucosal pH: a better predictor of multiorgan dysfunction syndrome than oxygen-derived variables in patients with sepsis. Chest 1993; 104: 225–9PubMedGoogle Scholar
  104. 104.
    Maynard N, Bihari D, Beale R, et al. Assessment of splanchnic oxygenation by gastric tonometry in patients with acute circulatory failure. JAMA 1993; 270: 1203–10PubMedGoogle Scholar
  105. 105.
    Creteur J, De Backer D, Vincent JL. A dobutamine test can disclose hepatosplanchnic hypoperfusion in septic patients. Am J Respir Crit Care Med 1999; 160: 839–45PubMedGoogle Scholar
  106. 106.
    Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism and gastric tonometric variables in septic shock: a prospective randomized study. Intensive Care Med 1997; 23: 282–7PubMedGoogle Scholar
  107. 107.
    Perkins MW, Dasta JF, DeHaven B. Physiologic implications of mechanical ventilation on pharmacokinetics. Drug Intell Clin Pharm 1989; 23: 316–23Google Scholar
  108. 108.
    Bonnet F, Richard C, Glaser P, et al. Changes in hepatic flow induced by continuous positive pressure ventilation in critically ill patients. Crit Care Med 1982; 10: 703–5PubMedGoogle Scholar
  109. 109.
    Jardin F, Farcot JC, Boisante L, et al. Influence of positive end-expiratory pressure on left ventricular performance. N Engl J Med 1981; 304: 387–92PubMedGoogle Scholar
  110. 110.
    Zamacona MK, Suarez E, Aguilera L, et al. Serum protein binding of propofol in critically ill patients. Acta Anaesthesiol Scand 1997; 41: 1267–72PubMedGoogle Scholar
  111. 111.
    Park GR, Pichard L, Tinel M, et al. What changes drug metabolism in critically ill patients? Anaesthesia 1994; 49: 188–91PubMedGoogle Scholar
  112. 112.
    Park GR, Miller E, Navapurkar V. What changes drug metabolism in critically ill patients? Serum inhibits the metabolism of midazolam in human microsomes. Anaesthesia 1996; 51: 11–5PubMedGoogle Scholar
  113. 113.
    Park GR, Miller E. What changes drug metabolism in critically ill patients? Effect of pre-existing disease on the metabolism of midazolam. Anaesthesia 1996; 51: 431–4PubMedGoogle Scholar
  114. 114.
    Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth 1996; 77: 32–49PubMedGoogle Scholar
  115. 115.
    Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997; 29: 1129–88PubMedGoogle Scholar
  116. 116.
    Iber H, Sewer MB, Barclay TB, et al. Modulation of drug metabolism in infectious and inflammatory diseases. Drug Metab Rev 1999; 31: 29–41PubMedGoogle Scholar
  117. 117.
    Tsutsumi M, Lasker JM, Shimizu M, et al. The intralobular distribution of ethanol-inducible P450 2E1 in rat and human liver. Hepatology 1989; 10: 437–46PubMedGoogle Scholar
  118. 118.
    Muller CM, Scierka A, Stiller RL. Nitric oxide mediates hepatic cytochrome P450 dysfunction induced by endotoxin. Anesthesiology 1996; 84: 1435–42PubMedGoogle Scholar
  119. 119.
    Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. Philadelphia (PA): Williams and Wilkins, 1994: 156–83Google Scholar
  120. 120.
    van Dalen R, Vree TB. Pharmacokinetics of antibiotics in critically ill patients. Intensive Care Med 1990; 16: S235–8PubMedGoogle Scholar
  121. 121.
    Duchin KL, Schrier RW. Interrelationship between renal haemodynamics, drug kinetics and drug action. Clin Pharmacokinet 1978; 3: 58–71PubMedGoogle Scholar
  122. 122.
    Bock HA. Pathophysiology of acute renal failure in septic shock: from prerenal to renal failure. Kidney Int 1998; 53: S15–8Google Scholar
  123. 123.
    Milne RW, Nation RL, Somogyi AA, et al. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol 1992; 34: 53–9PubMedGoogle Scholar
  124. 124.
    Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 1996; 31: 410–22PubMedGoogle Scholar
  125. 125.
    D’Honneur G, Gilton A, Sandouk P, et al. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. Anesthesiology 1994; 81: 87–93PubMedGoogle Scholar
  126. 126.
    Bauer TM, Haberthür C, Riem Ha H, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995; 346: 145–7PubMedGoogle Scholar
  127. 127.
    St Peter WL, Redic-Kill KA, Halstenson CE. Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet 1992; 22: 169–210PubMedGoogle Scholar
  128. 128.
    Jones EM, McMullin CM, Hedges AJ, et al. The pharmacokinetics of intravenous ciprofloxacin 400mg 12 hourly in patients with severe sepsis: the effect of renal function and intra-abdominal disease. J Antimicrob Chemother 1997; 40: 121–4PubMedGoogle Scholar
  129. 129.
    Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340: 207–14PubMedGoogle Scholar
  130. 130.
    De Paepe P, Belpaire FM, Rosseel MT, et al. The influence of hypovolemia on the pharmacokinetics and the electroencephalographic effect of propofol in the rat. Anesthesiology 2000; 93: 1482–90PubMedGoogle Scholar
  131. 131.
    Silverman HJ, Penaranda R, Orens JB, et al. Impaired β-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 1993; 21: 31–9PubMedGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  • Peter De Paepe
    • 1
  • Frans M. Belpaire
    • 1
  • Walter A. Buylaert
    • 2
  1. 1.Heymans Institute of PharmacologyGhent UniversityGhentBelgium
  2. 2.Department of Emergency MedicineGhent University HospitalGhentBelgium

Personalised recommendations